Thrombosis
News
NICE recommends edoxaban for VTE
Image by Keven MacKenzie The UK’s National Institute for Health and Care Excellence (NICE) has issued a draft guidance recommending the oral...
Conference Coverage
Routine screening sufficient for detecting occult cancer in patients with VTE
Key clinical point: Occult cancers in patients with a first unprovoked VTE are not nearly as common as previously thought, and limited screening...
Conference Coverage
High VTE recurrence risk persists for at least 3 years
The risk of recurrence following an initial episode of venous thromboembolism is highest in the first 3 months, but remains high for up to 3 years...
Conference Coverage
Statins showed no benefit in reducing risk of recurrent VTE
The use of statins showed no benefit in reducing the risk of recurrent venous thromboembolism in patients enrolled in phase III trials comparing...
News
Benefit of extended anticoagulation is temporary, study shows
Results of the PADIS-PE trial suggest that patients with a first episode of pulmonary embolism (PE) benefit from extended anticoagulation therapy...
News
NICE supports use of apixaban for VTE
Photo courtesy of the CDC The UK’s National Institute for Health and Care Excellence (NICE) has issued a final guidance recommending the...
Conference Coverage
Inhibitors increase burden of hemophilia care
TORONTO—When children with hemophilia develop inhibitors, their caregivers shoulder a greater burden, according to a pilot study. Researchers...
Conference Coverage
Pain problems prevalent in adults with hemophilia
TORONTO—A survey of adult hemophilia patients suggests there is room for improvement in assessing and managing disease-related pain. Roughly 85%...
Conference Coverage
Extended-interval dosing appears safe, effective
Photo courtesy of Biogen TORONTO—Full results of a phase 3 study support extended-interval dosing with a recombinant factor IX Fc fusion protein...
Conference Coverage
Anticoagulant antidote effective in healthy volunteers
TORONTO—An antidote to factor Xa inhibitors can safely reverse the anticoagulant effect of apixaban in healthy volunteers, results of the ANNEXA-A...
Conference Coverage
Long-term data support use of FVIII treatment
TORONTO—The antihemophilic factor turoctocog alfa is safe and effective long-term, according to interim data from the phase 3 guardian 2 trial....